Clinical inquiries. What is the evaluation and treatment strategy for Raynaud's phenomenon?
Tagliarino
Heather
H
Swedish Medical Center, Seattle, Washington, USA. htagliarino@sfm.fammed.washington.edu
Purdon
Michael
M
Jamieson
Barbara
B
Hoekzema
Grant
G
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D019317:Evidence-Based Medicine / Q000379:methods / Q000592:standards; D006801:Humans; D009543:Nifedipine / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011224:Prazosin / Q000627:therapeutic use; D011928:Raynaud Disease / Q000175:diagnosis* / Q000628:therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D014665:Vasodilator Agents; D009543:Nifedipine; D011224:Prazosin